Sphere Fluidics Successfully Closes a $2.5 million Series A Investment Round

CAMBRIDGE, England, February 20, 2013 /PRNewswire/ –

Sphere Fluidics, an early-stage, Cambridge-based company focusing on developing novel
products and services for single cell analysis, has just completed a $2.5 million
investment round. The investment syndicate was led by 24Haymarket and included the Royal
Society, Cambridge Enterprise Limited, Providence Investment Company Limited, University
of Cambridge Enterprise Fund, the London Business Angels Roundtable EIS Fund and a number
of individual angels from London (including members of the London Business Angels) and
Cambridge.

Sphere Fluidics Limited is a growing Life Sciences company, based on technology
originating from the Chemistry Department of Cambridge University. The Company has now
fully developed this technology into a novel platform for single cell analysis and
characterisation that enables the discovery and development of new biopharmaceuticals and
cell therapies and novel ways to study single cell diseases, such as cancer. Sphere
Fluidics has patented novel biochip systems that automatically process millions of
miniaturised (picolitre to nanolitre) tests in picodroplets enabling the discovery of the
one in a million cells or molecules that could be the next pharmaceutical industry
“blockbuster”.

Andrew Mackintosh, Chairman of Sphere Fluidics and Chief Executive of the Royal
Society Enterprise Fund, comments: “Sphere Fluidics is exactly the sort of early-stage,
high-potential company that the Royal Society Enterprise Fund was set up to support. The
business is an outstanding example of the successful translation of excellent science into
commercial potential. I am delighted that such a strong network of business angels is
supporting the company, bringing not only funding but extensive business experience and
contacts.

Ian Gray, a member of 24Haymarket and a new Company Director of Sphere Fluidics, says
“24Haymarket are delighted to participate in the next phase of the Company’s growth. This
growth will be based on the foundations of world-class science and strong focused
management, and will result from sales to and collaborations with innovative forward
thinking customers and contacts.”

Frank Craig, Sphere Fluidics’ CEO, comments, “We are very pleased to close this round
as it gives us the resources to further develop our business. There was strong interest in
the company and we were pleased to welcome 24Haymarket into an impressive syndicate of
investors. I am excited about further applying our exciting technology to major Life
Sciences markets and accelerating its commercialisation”.

        Press Contact
        Sphere Fluidics Limited. Contact Dr Frank Craig on:
        E-mail: Frank.Craig@spherefluidics.com
        Tel: + 44 (0)1223-389004.

SOURCE Sphere Fluidics Limited